San Francisco-based Cellares has extended its Series D financing to USD 327 million following a USD 50 million growth equity investment from Prime Radiant Fund SLP SICAV-RAIF, a Luxembourg-based fund advised by Prime Radiant Partners. The company describes itself as the first Integrated Development and Manufacturing Organization (IDMO) for cell therapies, providing automated manufacturing services to drug sponsors across development and commercial stages.
Prime Radiant joins an existing investor group that includes ARK Invest, investment funds managed by BlackRock, Eclipse, T. Rowe Price Investment Management, Duquesne Family Office, Baillie Gifford, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors. The company said the capital will finance operations through commencement of commercial-scale manufacturing and a planned IPO in 2027, as well as support its European expansion in Leiden, the Netherlands. Cellares' first commercial-scale Smart Factory operates in Bridgewater, New Jersey, with additional facilities under construction in Japan.
Prime Radiant Partners, which maintains offices in New York, Milan, and Munich, specializes in middle-market healthcare and life sciences private equity across North America and Europe. Walid Gardezi, Co-Founder and Partner at Prime Radiant Partners, cited the firm's operational roots in European pharma services as a factor in its ability to support Cellares' continental expansion.
The cell therapy manufacturing sector presents a significant bottleneck for drug developers. Conventional contract development and manufacturing organizations (CDMOs) face capacity and cost constraints that Cellares argues its automated platform can overcome. Competitors in the cell therapy CDMO space include WuXi AppTec's cell and gene therapy division, Lonza, and Thermo Fisher Scientific's cell therapy business, among others. Cellares differentiates itself through a fully automated, closed-system approach rather than manual or semi-automated manufacturing.
Cellares operates two core platforms: the Cell Shuttle, an end-to-end automated cell therapy manufacturing system, and Cell Q, an automated in-process and release quality control platform. The company reports that the Cell Shuttle has demonstrated a 100% automation success rate across more than a dozen processes and is the first cell therapy manufacturing platform to receive the US FDA's Advanced Manufacturing Technology (AMT) designation. The platform is designed to produce up to 10 times more cell therapy batches than conventional CDMOs with comparable footprint and headcount, which the company said results in lower per-batch manufacturing costs.